Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Yuehui Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 4, Drug Design, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality.
Abstract (Originalsprache)
Aberrant activation of the FGFR4 signaling pathway, often driven by FGFR4 genetic alterations, has been implicated in the progression of hepatocellular carcinoma (HCC), highlighting FGFR4 as a promising therapeutic target for FGFR4-driven HCC. Although numerous selective covalent FGFR4 inhibitors have been discovered, developing FGFR4 PROTACs could offer great advantages as an alternative and complementary strategy for HCC therapy. In this study, we have designed a series of covalent degraders by conjugating the FGFR4-selective inhibitor H3B-6527 to E3 ubiquitin ligase-recruiting ligands via diverse linkers. Among them, we identified compound V1 as the first PROTAC capable of degrading FGFR4, with a DC₅₀ value of 0.84 μM and Dmax rate of 80%. Further evaluation demonstrated that V1 promotes efficient and sustained FGFR4 degradation through a ubiquitin-proteasome system (UPS)-dependent pathway and exhibited moderate inhibitory effects on cell proliferation in JHH-7 cells. Moreover, the covalent binding model of compound V1 with FGFR4 was also characterized by LC-MS/MS. These findings suggest that V1 is a promising lead compound for the development of FGFR4-targeted PROTACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, PR China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, PR China.
- Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China.
- Chongqing Key Laboratory of Quality Control and Safety Evaluation of APIs, Chongqing Medical University, Chongqing 400016, PR China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, PR China. Electronic address: zhuqihua@cpu.edu.cn.
- Department of Medicinal Chemistry, College of Pharmacy, Chongqing Medical University, Chongqing 400016, PR China; Chongqing Key Laboratory of Quality Control and Safety Evaluation of APIs, Chongqing Medical University,…
Förderung
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Li, Y., Du, Y., Deng, P., Yang, Y., Wu, Y., Sun, X., Chen, Q., Yang, J., Zhu, Q., Gan, Z., & Long, R. (2026). Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110495
Vancouver
Li Y, Du Y, Deng P, Yang Y, Wu Y, Sun X, et al. Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110495
BibTeX
@article{Li2026,
author = {Li, Yuehui and Du, Yu and Deng, Ping and Yang, Yi and Wu, Yue and Sun, Xiaomeng and Chen, Qiuzhu and Yang, Juntong and Zhu, Qihua and Gan, Zongjie and Long, Rui},
title = {Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110495}
}
EUVIMED